Innovent Biologics to present new obesity and metabolic drug data at ADA 2026 conference.

Innovent Biologics announced it will showcase multiple clinical and preclinical results for its obesity and metabolic disease treatments, including mazdutide and next-generation drugs, at the 2026 American Diabetes Association Scientific Sessions. The presentations cover studies on adults and adolescents with obesity and type 2 diabetes, highlighting mazdutide's benefits in weight loss and glycemic control. Innovent also revealed data on new oral GLP-1 receptor agonists and other innovative therapies aimed at improving treatment tolerability and effectiveness. These developments position Innovent as a rising leader in obesity and metabolic disease treatment globally.